Skip to content
The Nexus
DossierENTITY

Bristol-Myers

Coverage of Bristol-Myers in the Nexus archive.

Earliest in view: May 12 · 06:38 UTCMost recent: Aug 3 · 18:44 UTC
Co-mentioned in this coverage
Iranplace2Donald Trumpperson2AstraZenecaorganization2United Statesplace2Japanplace2Michigan Cyclosporiasis Outbreaktopic1Cornynperson1Tillisperson1Blancheperson1Omanplace1Hormuzplace1AWSorganization1Visaorganization1BioCatchorganization1Gary Cohnperson1Apolloorganization1Austinplace1Department of Justiceorganization1Senateorganization1chip stockstopic1
Recent coverage
  • BUSINESSAug 3 · 18:44 UTCBLOOMBERG
    Bloomberg News Now

    The article covers a growing cyclosporiasis outbreak in Michigan leading to food stock declines, bipartisan support for Blanche for Attorney General, advancing Iran-Oman Hormuz talks following Trump's attack halt, easing oil prices and market rallies, AWS's fastest growth in five years, AstraZeneca's potential mega-merger with Bristol-Myers, Visa's acquisition of BioCatch, U.S.-Japan yen defense measures, U.S. manufacturing hitting a four-year high, and Apollo's selection of Austin for its second headquarters.

  • BUSINESSAug 3 · 10:56 UTCBLOOMBERG
    Bloomberg News Now

    Trump pushes for new Iran negotiations, the DOJ ends a controversial anti-weaponization fund, and the Senate unveils a short-term funding bill. Chip stocks are in focus after a July selloff, while the U.S. and Japan intervene to support yen markets. AstraZeneca explores a merger with Bristol-Myers.

  • BUSINESSMay 12 · 06:38 UTCBLOOMBERG
    Bristol-Myers Inks Up to $15 Billion Licensing Deal With Hengrui

    Bristol-Myers has signed a licensing deal worth up to $15 billion with Jiangsu Hengrui Pharmaceuticals. The deal is for branding and licensing of certain products. This partnership is expected to expand the reach of both companies.